SPY302.15-0.82 -0.27%
DIA253.27-1.08 -0.42%
IXIC9,387.87+18.88 0.20%

Raymond James Maintains Strong Buy on Health Catalyst, Lowers Price Target to $40

Raymond James analyst John Ransom maintains Health Catalyst (NASDAQ:HCAT) with a Strong Buy and lowers the price target from $46 to $40.

Benzinga · 05/13/2020 11:12

Raymond James analyst John Ransom maintains Health Catalyst (NASDAQ:HCAT) with a Strong Buy and lowers the price target from $46 to $40.